EADO CONGRESS SCIENTIFIC POGRAMME · 10:00–10:18 The beginners guide to avoid mistakes Giuseppe...

SCIENTIFIC POGRAMME16th EADO CONGRESS

4 F I N A L P R O G R A M M E

22-25 APRIL, 2020, RADISSON BLU HOTEL LIETUVA, VILNIUS, LITHUANIA

ALFA HALL BETA HALL ZETA HALL

09:00–12:15 DERMATOSCOPY COURSE 1 SCOPE SATELLITE SYMPOSIUM AT THE EADO

12:15–13:00 COFFEE BREAK, VISIT TO THE EXHIBITION & POSTER VIEWING

13:00–13:15 OPENING CEREMONY

13:15–14:15 KEYNOTE LECTURES 1Skin cancer preventionClassification of melanoma

14:30–15:30 INDUSTRY SATELLITE SYMPOSIUM 1

15:30–17:00 SYMPOSIUM 1Advanced BCC classification and treatment

SYMPOSIUM 2Biology of skin cancer


17:30–18:45 SYMPOSIUM 3Management of nevi

SYMPOSIUM 4Barriers to access to innovative medicines and successful access schemes in Europe: multi–stakeholder panel discussion

19:00–22:30 NETWORKING EVENING

Wednesday, April 22

Wed

nesd

ay, A

prill

22

5w w w . e a d o 2 0 2 0 . c o m


09:00–12:15 DERMATOSCOPY COURSE 1CHAIRS: Iris Zalaudek (Trieste, Italy)

Aimilios Lallas (Thessaloniki, Greece)Harald Kittler (Vienna, Austria)

09:00–09:18 Pattern recognition and pattern analysis Harald Kittler (Vienna, Austria)

09:20–09:38 Colors: Black beauties and pink panthers Aimilios Lallas (Thessaloniki, Greece)

09:40–09:58 Case studies: What would a novice do Claudio Conforti (Trieste, Italy)

10:00–10:18 The beginners guide to avoid mistakes Giuseppe Argenziano (Naples, Italy)

10:20–10:38 Gray Color and its significance Iris Zalaudek (Trieste, Italy)

10:40–10:58 Nodules on the face–clues for benign and malignant lesions Susanna Puig (Barcelona, Spain)

11:00–11:18 Case studies: Monitoring–when to cut out and when to continue Josep Malvehy (Barcelona, Spain)

11:20–11:38 What is so special on special locationsLuc Thomas (Lyon, France)

11:40–11:58 Case studies: Real lifeLidija Kandolf–Sekulovic (Belgrade, Serbia)

12:00–12:13 Panel discussion

12:15–13:00 LUNCH BREAK. VISIT TO THE EXHIBITION & POSTER VIEWING

13:00 – 13:15 OPENING CEREMONYCHAIRS: Matilda Bylaitė–Bučinskienė (Vilnius, Lithuania)

Claus Garbe (Tuebingen, Germany)

13:15–14:15 KEYNOTE LECTURES 1CHAIRS: Matilda Bylaitė–Bučinskienė (Vilnius, Lithuania)


13:15–13:45 Skin cancer prevention Jean Jacques Grob (Marseille, France)

13:45–14:15 Classification of melanoma Boris Bastian (San Francisco, USA)


ALFA HALL

ALFA HALL

ALFA HALL

ALFA HALL

Wednesday, April 22

Dermatoscopy course Scope satellite symposium at the EADO Keynote lecturesOpening ceremony Industry satellite symposium

Closing ceremony & awards Industry satellite lunch symposiumSymposium Social meeting

Wed

nesd

ay, A

prill

22




15:30–17:00 SYMPOSIUM 1ADVANCED BCC CLASSIFICATION AND TREATMENTCHAIRS: Jean Jacques Grob (Marseille, France)

Nicole Basset–Seguin (Paris, France)

15:30–15:45 How to classify and stage BCC? Jean Jacques Grob (Marseille, France)

15:48–16:03 SMO inhibitors Nicole Basset–Seguin (Paris, France)

16:06–16:21 Best strategies using SMO inh (on/off intermittent, neoadjuvant.) Brigitte Dréno (Nantes, France)

16:24–16:39 What place for immunotherapy in BCC? Axel Hauschild (Kiel, Germany)

16:42–16:57 Update: guidelines Ketty Peris (Rome, Italy)

17:00–17:30 COFFEE BREAK. VISIT TO THE EXHIBITION & POSTER VIEWING

17:30–18:45 SYMPOSIUM 3MANAGEMENT OF NEVICHAIRS: Giuseppe Argenziano (Naples, Italy)

Harald Kittler (Vienna, Austria)

17:30–17:42 The comparative approach and beyond Giuseppe Argenziano (Naples, Italy)

17:45–17:57 The “dysplastic” nevus Harald Kittler (Vienna, Austria)

18:00–18:12 The “Spitz” nevus Aimilios Lallas (Thessaloniki, Greece)

18:15–18:27 Digital monitoring: best indications Elvira Moscarella (Naples, Italy)

18:30–18:42 The blue and the non–blue congenital nevus Susanna Puig (Barcelona, Spain)

19:00–22:30 NETWORKING EVENING NATIONAL GALLERY OF ARTKonstitucijos ave. 22

ALFA HALL

ALFA HALL

Wednesday, April 22

Wed

nesd

ay, A

prill

22



7w w w . e a d o 2 0 2 0 . c o m


09:00–12:15 SCOPE SATELLITE SYMPOSIUM AT THE EADO CHAIRS: Alexandra Geusau (Vienna, Austria)

Deniz Seckin (Ankara, Turkey)

09:00–09:05 Welcome and introduction

09:05–09:25 Non–melanoma skin cancer incidence after organ transplantation Jan Nico Bouwes Bavinck (Leiden, The Netherlands)

09:28–09:48 Skin cancer following solid organ transplantation–the role of immunosuppression (including Q&A) Oscar Colegio (New York, USA)

09:51–10:11 AK therapy and skin cancer prevention in high–risk transplant recipients (including Q&A) Klara Mosterd (Maastricht, The Netherlands)

10:14–10:34 Checkpoint inhibitor therapy for cancer in solid organ transplant recipients: A systematic review (including Q&A) Celeste Lebbé (Paris, France)

10:40 –11:00 COFFEE BREAK

CHAIRS: Charlotte M. Proby (Dundee, UK)Jan Nico Bouwes Bavinck (Leiden, The Netherlands)

11:00–11:20 Rare skin cancers and immunosuppression (including Q&A) Catherine Harwood (London, UK)

11:23–11:43 Skin cancer in chronic lymphocytic leukaemia Ulrike Leiter–Stöppke (Tuebingen, Germany) Andreas Meiwes (Tuebingen, Germany)

CHAIRS: Oscar Colegio (New York, USA) Carla Ferrandiz–Pulido (Barcelona, Spain)Veronique del Marmol (Brussels, Belgium)Mirjam Nägeli (Zurich, Switzerland)Elsemieke Plasmeijer (Leiden, The Netherlands)

11:45–12:20 Tumour Board and expert panel discussion: difficult to treat cases Case 1, Case 2, Case 3

12:20–12:30 Closing remarks

12:15–13:00 VISIT TO THE EXHIBITION & POSTER VIEWING

BETA HALL

Wednesday, April 22

Wed

nesd

ay, A

prill

22






Wednesday, April 22



15:30–17:00 SYMPOSIUM 2BIOLOGY OF SKIN CANCERCHAIRS: Amaya Virós (Manchester, UK)

Reinhard Dummer (Zurich, Switzerland)

15:30–15:42 Extramammary paget Thierry Nordmann (Zurich, Switzerland)

15:45–15:57 New perspectives for the pathogenesis of cutaneous melanoma Amaya Virós (Manchester, UK)

16:00–16:12 MCC where does it come from Sara Valpione (Manchester, UK)

16:15–16:27 Biology of Dermatofibrosarcoma protuberans Celeste Lebbé (Paris, France)

16:30–16:42 New aspects of cutaneous lymphomasReinhard Dummer (Zurich, Switzerland)

16:45–16:57 The molecular signature of fast-growing melanomas Caroline Gaudy-Marqueste (Marseille, France)


17:30–18:45 SYMPOSIUM 4 BARRIERS TO ACCESS TO INNOVATIVE MEDICINES AND SUCCESSFUL ACCESS SCHEMES IN EUROPE: MULTI-STAKEHOLDER PANEL DISCUSSIONCHAIRS: Lidija Kandolf-Sekulovic (Belgrade, Serbia)

Ana-Maria Forsea (Bucharest, Romania)

17:30–17:45 “Innovative medicines: the challenge of combining swift patient access and health system sustainability.” Vision of the Task Force Access to Medicines of ECL Ward Rommel (Brussels, Belgium)

17:49–18:04 TBD Igoris Baikovskis (Vilnius, Lithuania)

18:07–18:22 Patient Access to Innovation–Is the industry perspective different? Alexander Roediger (Kriens, Switzerland)

18:25–18:40 When survival depends on access to expensive therapies. Lessons from the Melanoma Patient Network Europe Bettina Ryll (Stockholm, Sweden)

BETA HALL

BETA HALL

Wed

nesd

ay, A

prill

22

9w w w . e a d o 2 0 2 0 . c o m


Thursday, April 23ALFA HALL BETA HALL ZETA HALL

08:30–10:00 SYMPOSIUM 5New diagnostic devises in skin cancers

SYMPOSIUM 6Predictive markers for immunotherapy in melanoma


10:30–12:00 SYMPOSIUM 7Medical treatment of melanoma

SYMPOSIUM 8Melanoma surgery

FREE COMMUNICATIONS 1

12:15–13:15 INDUSTRY SATELLITE LUNCH SYMPOSIUM 1

13:15–14:15 KEYNOTE LECTURES 2


SYMPOSIUM 9Update on management of actinic keratoses

WORKSHOP 1Spitzoid tumors

15:30–16:00 COFFEE BREAK, VISIT TO THE EXHIBITION & E-POSTER VIEWING


SYMPOSIUM 10Skin cancer prevention & screening

17:00–18:30 SYMPOSIUM 11Adjuvant treatment in melanoma

SYMPOSIUM 12The new European BCC guidelines


19:00–22:00 EADO BOARD MEETING

Thur

sday

, Apr

il 23




08:30–10:00 SYMPOSIUM 5NEW DIAGNOSTIC DEVISES IN SKIN CANCERSCHAIRS: Josep Malvehy (Barcelona, Spain)

Giovanni Pellacani (Modena, Italy)

08:30–08:45 Confocal microscopy for melanoma diagnosis: evidence from Cochrane analysis to randomized trial Giovanni Pellacani (Modena, Italy

08:48–09:03 Confocal microscopy for other skin cancers: in vivo and ex vivo applications Javiera Perez (Barcelona, Spain)

09:06–09:21 OCT for non-melanoma skin cancer Julia Welzel (Augsburg, Germany)

09:24–09:39 Linear-scanning OCT Mariano Suppa, (Belgium, Brussels)

09:42–09:56 Other non-imaging tools and Artificial Intelligence Josep Malvehy (Barcelona, Spain)


10:30–12:00 SYMPOSIUM 7MEDICAL TREATMENT OF MELANOMACHAIRS: Dirk Schadendorf (Essen, Germany)

Michael Postow (New York, USA)

10:30–10:50 What do we know about sequencing and combining? Dirk Schadendorf (Essen, Germany)

10:53–11:13 Are neoadjuvant trials for translational research or a registrational pathway for new treatments? Alexander van Akkooi (Amsterdam, The Netherlands)

11:16–11:36 Where are we 5-years later with combined CTLA-4 + PD1 checkpoint blockade? Celeste Lebbe (Paris, France)

11:39–11:59 Where are we 5-years later with BRAF directed targeted therapy? Helen Gogas (Athens, Greece)


13:15–14:15 KEYNOTE LECTURES 2CHAIRS: Hubert Pehamberger (Vienna, Austria)

Jean Jacques Grob (Marseille, France)

13:15–13:45 Cancer syndromesRoland Kaufmann (Frankfurt, Germany)

13:45–14:15 TBD

ALFA HALL

ALFA HALL

ALFA HALL

ALFA HALL

Thursday, April 23

Thur

sday

, Apr

il 23



11w w w . e a d o 2 0 2 0 . c o m





17:00–18:30 SYMPOSIUM 11ADJUVANT TREATMENT IN MELANOMACHAIRS: Caroline Robert (Villejuif, France)

Jessica Hassel (Heidelberg, Germany)

17:00–17:15 Adjuvant immunotherapiesCaroline Robert (Villejuif, France)

17:18–17:33 Adjuvant targeted therapiesJessica Hassel (Heidelberg, Germany)

17:36–17:51 Adjuvant therapy in stage II melanomaAlexander Eggermont (Utrecht, The Netherlands)

17:54–18:09 Neoadjuvant approachesAlexander van Akkooi (Amsterdam, The Netherlands)

18:12–18:27 Panel discussion

19:00–22:00 EADO BOARD MEETING

08:30–10:00 SYMPOSIUM 6PREDICTIVE MARKERS FOR IMMUNOTHERAPY IN MELANOMACHAIRS: Brigitte Dréno (Nantes, France)

Christoph Hoeller (Vienna, Austria)

08:30–08:45 Predictive biomarkers for immunotherapy in advanced melanoma: Moving toward a personalized medicine? Reinhard Dummer (Zurich, Switzerland)

08:48–09:03 Circulating biomarkers predictive of tumor response to immunotherapyChristoph Hoeller (Vienna, Austria)

09:06–09:21 Cell cycle regulator genes predicting responsiveness to melanoma immune therapy? Martin Röcken (Tübingen, Germany)

09:24–09:39 Predictive markers of induced immune-related adverse events to immunotherapy Brigitte Dréno (Nantes, France)

09:42–09:57 PET Imaging and early Immunotherapy Response: a new predictive tool Dominik Bercazcy (Vienna, Austria)

ALFA HALL

ALFA HALL

ALFA HALL

BETA HALL

Thursday, April 23



Thur

sday

, Apr

il 23





10:30–12:00 SYMPOSIUM 8MELANOMA SURGERYCHAIRS: Roland Kaufmann (Frankfurt, Germany)

David Moreno (Seville, Spain)

10:30–10:42 Removal of nevi–Can we prevent Melanoma?Ricardo Vieira (Coimbra, Portugal)

10:45–10:57 Surgical standards in primary melanoma–Considerations of defect repairMichael Mühlstädt (Geneva, Switzerland)

11:00–11:12 Special aspects in surgery of Lentigo maligna melanomaCristina Magnoni (Modena, Italy)

11:15–11:27 Special aspects in surgery of acral MelanomasRoland Kaufmann (Frankfurt am Main, Germany)

11:30–11:42 SNB and CLND–current approaches and modifications David Moreno-Ramirez (Seville, Spain)

11:45–12:57 Removal of distant Metastases–what are the indications and benefits? Alessandro Testori (Milan, Italy)

14:30–15:30 SYMPOSIUM 9UPDATE ON MANAGEMENT OF ACTINIC KERATOSES CHAIRS: Thomas Dirschka (Wuppertal, Germany)

Dimitrios Sgouros (Athens, Greece)

14:30–14:48 Actinic keratosis: Patients` perception and treatment barriersDimitrios Sgouros (Athens, Greece)

14:50–15:08 Evaluation of treatment outcome in actinic keratosis. What does it mean for efficacy? Rolf-Markus Szeimies (Recklinghausen, Germany)

15:10–15:28 News from the field–recent research on actinic keratosis Thomas Dirschka (Wuppertal, Germany)

15:30–16:00 COFFEE BREAK VISIT TO THE EXHIBITION & POSTER VIEWING

BETA HALL

BETA HALL



Thursday, April 23

Thur

sday

, Apr

il 23

13w w w . e a d o 2 0 2 0 . c o m


16:00–17:00 SYMPOSIUM 10SKIN CANCER PREVENTION & SCREENINGCHAIRS: Veronique del Marmol (Brussels, Belgium)

Matilda Bylaitė-Bučinskienė (Vilnius, Lithuania)Dagmar Whitaker (Cape Town, South Africa)

16:00–16:12 Skin cancer awareness and early detection issues in the Baltic regionMatilda Bylaitė-Bučinskienė (Vilnius, Lithuania)

16:15–16:27 Sunscreen: the debateVeronique del Marmol (Brussels, Belgium)

16:30–16:42 Early detection for the biggest killers Ana-Maria Forsea (Bucharest, Romania)

16:45–16:57 Skin cancer prevention and screening–what works and what doesn’t workDagmar Whitaker (Cape Town, South Africa)

17:00–18:30 SYMPOSIUM 12THE NEW EUROPEAN BCC GUIDELINESCHAIRS: Ketty Peris (Rome, Italy)

Maria Concetta Fargnoli (L’Aquila, Italy)

17:00–17:12 How to define common and difficult-to-treat BCCKetty Peris (Rome, Italy)

17:15–17:27 Which are the indications for surgical excision?Roland Kaufmann (Frankfurt, Germany)

17:30–17:42 When should we consider topical or destructive treatments?Maria Concetta Fargnoli (L’Aquila, Italy)

17:45–17:57 Which BCCs require medical therapy?Axel Hauschild (Kiel, Germany)

18:00–18:12 Which follow-up schedule for which patients? Physicians recommendations and patient’s information.Veronique Bataille (London, UK)

18:15–18:27 How do we manage BCC lesions in NBCCS patients?Iris Zalaudek (Trieste, Italy)

BETA HALL

BETA HALL



Thursday, April 23

Thur

sday

, Apr

il 23




Thursday, April 2310:30–12:00 FREE COMMUNICATIONS 1

GENETICS, BIOLOGY, DIAGNOSIS AND STAGING OF MELANOMACHAIRS: Veronique Bataille (London, UK)

Antonio Costanzo (Milan, Italy)

10:30–10:40 FC01 Defining the prognostic role of microRNAs in cutaneous melanoma Emi Dika (Bologna, Italy)

10:43–10:53 FC02 MX2 is involved in regulation of cell cycle in melanoma cells Marina Juraleviciute (Oslo, Norway)

10:56–11:06 FC03 AMBLor: a prognostic and companion biomarker for improved stratification of adjuvant therapy for AJCC stage II melanomaRob Ellis (Newcastle, UK)

11:09–11:19 FC04 Prognostic Risk Models Following AJCC Stage 1 Melanoma: A Systematic ReviewPatience Kunonga (Newcastle, UK)

11:22–11:32 FC05 Optimal Surveillance Strategies for AJCC Stage I Melanoma: The Health Technology Assessment (HTA) ApproachDiarmuid Coughlan (Newcastle, UK)

11:35–11:45 FC06 Validation of a clinicopathological and gene expression profile (CP-GEP) model to identify stage I and II melanoma patients at high risk for disease relapse E.E.A.P. Mulder (Amsterdam, The Netherlands)

11:48–11:58 FC07 Diagnostic accuracy of high-resolution ultrasound and fine needle aspiration for recurrence and locoregional metastases at follow-up in patients treated initially for stage I or stage II melanoma: a systematic review Margaret Astin (Newcastle, UK)

14:30–15:30 WORKSHOP 1SPITZOID TUMORSCHAIRS: Laura Held (Friedrichshafen, Germany)

Aimilios Lallas (Thessaloniki, Greece)

14:30–14:50 Histopathology, immunohistochemistry and molecular alterations in Spitzoid lesionsLaura Held (Friedrichshafen, Germany)

14:55–15:15 Clinical and dermatoscopic morphology of spitzoid tumors and management recommendationsAimilios Lallas (Thessaloniki, Greece)

15:20–15:30 Discussion


ZETA HALL

ZETA HALL



Thur

sday

, Apr

il 23

15w w w . e a d o 2 0 2 0 . c o m


Thursday, April 2317:00–18:30 FREE COMMUNICATIONS 2

NON-MELANOMA SKIN CANCER CHAIRS: Alvydas Česas (Klaipėda, Lithuania)

Raimonds Karls (Riga, Latvia)

17:00–17:12 FC08 Surgery versus combined treatment with Curettage and Imiquimod for Nodular basal cell carcinoma (SCIN): 1-year results of a non-inferiority, randomized controlled trial Kelly Sinx (Maastricht, The Netherlands)

17:15–17:27 FC09 Daily practice data on 8 years’ experience with vismodegib in the Netherlands Klara Mosterd (Maastricht, The Netherlands)

17:30–17:42 FC10 Improved sun protection after melanoma diagnosis improves survival Ichiro Okamoto (Vienna, Austria)

17:45–17:57 FC11 HeberFERON as a therapeutic option for the treatment of advanced, high risk and multiple basal cell carcinomas Iraldo Bello Rivero (Havana, Cuba)

18:00–18:12 FC12 Neoadjuvant Vismodegib and Mohs Micrographic Surgery for Locally Advanced Periocular Basal Cell Carcinoma Gonzalez Abel (Buenos Aires, Argentina)

18:15–18:27 FC13 Intralesional oncolytic virotherapy results in tumor regression in cutaneous B-cell lymphoma Egle Ramelyte (Zurich, Switzerland)

ZETA HALL



Thur

sday

, Apr

il 23




Friday, April 24ALFA HALL BETA HALL ZETA HALL

08:30–10:00 SYMPOSIUM 13Advanced SCC

SYMPOSIUM 14Who should receive adjuvant therapy in melanoma


10:30–12:00 SYMPOSIUM 15Difficult to treat subtypes of melanoma

SYMPOSIUM 16The new European SCC guidelines



13:15–14:15 KEYNOTE LECTURES 3What is new in melanoma?What is new in keratinocyte skin cancer?


SYMPOSIUM 17Local therapies in melanoma

WORKSHOP 2Photodynamic therapy


16:00–17:00 SYMPOSIUM 18Cutaneous lymphoma

17:00–18:30 SYMPOSIUM 19Melanoma metastasis

SYMPOSIUM 20Management of cutaneous toxicities


Frid

ay, A

pril

24

17w w w . e a d o 2 0 2 0 . c o m


Friday, April 24



08:30–10:00 SYMPOSIUM 13ADVANCED SCCCHAIRS: Axel Hauschild (Kiel, Germany)

Ulrike Leiter-Stöppke (Tuebingen, Germany)

08:30–08:45 Does surgery still play a role in advanced SCC? Roland Kaufmann (Frankfurt, Germany)

08:48–09:03 Impact of irradiation in the adjuvant and advanced setting Rita Steponavičienė (Vilnius, Lithuania)

09:06–09:21 Chemotherapie and EGFR antibodies for advanced SCC Eve Malbec (Bobigny, France)

09:24–09:39 PD-1 antibodies for advanced SCC patients Ulrike Leiter-Stöppke (Tuebingen, Germany)

09:42–09:57 Future aspects and new clinical trials for PD-1 antibodies Axel Hauschild (Kiel, Germany)


10:30–12:00 SYMPOSIUM 15DIFFICULT TO TREAT SUBTYPES OF MELANOMACHAIRS: Lucie Heinzerling (Erlangen, Germany)

Céleste Lebbé (Paris, France)

10:30–10:50 Lentigo maligna Eduardo Nagore (Valencia, Spain)

10:53–11:13 Mucosal melanoma TBD

11:16–11:36 Uveal Melanoma Lucie Heinzerling (Erlangen, Germany)

11:39–11:59 Melanoma in organ transplant recipients Celeste Lebbé (Paris, France)


13:15–14:15 KEYNOTE LECTURES 3CHAIRS: Ketty Peris (Rome, Italy)

Michael Postow (New York, USA)

13:15–13:45 What is new in melanoma?Michael Postow (New York, USA)

13:45–14:15 What is new in keratinocyte skin cancer?Axel Hauschild (Kiel, Germany)

ALFA HALL

ALFA HALL

ALFA HALL

ALFA HALL

Frid

ay, A

pril

24




Friday, April 24





16:00–17:00 SYMPOSIUM 18CUTANEOUS LYMPHOMACHAIRS: Emannuella Guenova (Zurich, Switzerland)

Rudolf Stadler (Minden, Germany)

16:00–16:10 The blood signature of erythrodermia Patrick M. Brunner (Vienna, Austria)

16:12–16:22 Diagnostic clues for cutaneous T lymphomas Maxime Batistella (Paris, France)

16:24–16:34 Prognostic factors for cutaneous T cell lymphomas Julia Scarisbrick (Birmingham, UK)

16:36–16:46 Treatment of early stage cutaneous T cell lymphoma: state of the artEmannuella Guenova (Zurich, Switzerland)

16:48–16:58 Treatment of late stage cutaneous T cell lymphoma: state of the artRudolf Stadler (Minden, Germany)

17:00–18:30 SYMPOSIUM 19MELANOMA METASTASISCHAIRS: Maximilian Gassenmaier (Tuebingen, Germany)

Friedegund Meier (Dresden, Germany)

17:00–17:15 Patients with elevated LDHTBD

17:18–17:32 Reversing a cold into a hot tumorOlivier Michielin (Lausanne, Switzerland)

17:35–17:50 TBDTeresa Amaral

17:53–18:08 TBDMaximilian Gassenmaier (Tuebingen, Germany)

18:11–18:26 TBDFriedegund Meier (Dresden, Germany)

ALFA HALL

ALFA HALL

ALFA HALL

Frid

ay, A

pril

24

19w w w . e a d o 2 0 2 0 . c o m


Friday, April 2408:30–10:00 SYMPOSIUM 14

WHO SHOULD RECEIVE ADJUVANT THERAPY IN MELANOMA?CHAIRS: Caroline Gaudy-Marqueste (Marseille, France)

Bastian Schilling (Wuerzburg, Germany)

08:30–08:50 Who should receive adjuvant therapy in melanoma in stage IV?Dirk Schadendorf (Essen, Germany)

08:53–09:13 Who should receive adjuvant therapy in melanoma in stage III?Bastian Schilling (Wurzburg, Germany)

09:16–09:36 Who should receive adjuvant therapy in melanoma in stage II?Caroline Gaudy-Marqueste (Marseille, France)

09:39–09:59 Who should receive adjuvant targeted therapy or adjuvant immunotherapy?Caroline Robert (Paris, France)

10:00–10:30 COFFEE BREAK. VISIT TO THE EXHIBITION & POSTERS

10:30–12:00 SYMPOSIUM 16THE NEW EUROPEAN SCC GUIDELINESCHAIRS: David Moreno (Seville, Spain)

Ricardo Vieira (Coimbra, Portugal)

10:30–10:45 Risk assessment and staging Nicolle Kelleners-Smeets (Maastricht, The Netherlands)

10:48–11:03 Standard surgery and Mohs for primary BCC Ricardo Vieira (Coimbra, Portugal)

11:06–11:21 Alternatives to surgery in selected cases Roland Kaufmann (Frankfurt, Germany)

11:24–11:39 Surgery for regional nodal disease David Moreno (Seville, Spain)

11:42–11:57 Systemic treatments for advanced SCC Ketty Peris (Rome, Italy)

14:30–15:30 SYMPOSIUM 17LOCAL THERAPIES IN MELANOMACHAIRS: Robert H.I. Andtbacka (Boston, USA)

Christoph Hoeller (Vienna, Austria)

14:30–14:47 TBDTBD

14:50–15:07 TBDTBD

15:10–15:27 TBDTBD

BETA HALL

BETA HALL

BETA HALL

Frid

ay, A

pril

24




Friday, April 2415:30–16:00 COFFEE BREAK. VISIT TO THE EXHIBITION & E-POSTER

17:00–18:30 SYMPOSIUM 20MANAGEMENT OF CUTANEOUS TOXICITIES CHAIRS: Pauline Tetu (Paris, France)

Caroline Robert (Villejuif, France)

17:00–17:25 Management of cutaneous toxicites related to immunotherapies Caroline Robert (Villejuif, France)

17:30–17:55 Management of cutaneous toxicites related to BRAF MEK inhibitors Pauline Tetu (Paris, France)

18:00–18:25 Management of cutaneous toxicities of emergent therapies in oncologyVincent Sibaud (Toulouse, France)

10:30–12:00 FREE COMMUNICATIONS 3MELANOMA TREATMENTCHAIRS: Susanna Puig (Barcelona, Spain)

Željko Mijušković (Belgrade, Serbia)

10:30–10:40 FC14 Real-world outcomes on health-related quality of life in the non-interventional study NICO in Germany Peter Mohr (Buxtehude, Germany)

10:43–10:53 FC15 Prognosis and management of BRAF V600E-mutated pregnancy-associated melanoma Dimitrios C. Ziogas (Athens, Greece)

10:56–11:06 FC16 First-line immunotherapy with nivolumab plus ipilimumab versus targeted therapy with BRAF plus MEK inhibitors in patients with BRAF-mutant advanced melanoma: A real-world analysis Anna C. Pavlick (Princeton, USA)

11:09–11:19 FC17 Real-world efficacy of anti-PD-1 antibodies in advanced subungual melanoma: The large multicenter retrospective Japanese Acral Melanoma PD-1 (JAMP) study of 70 cases Yasuhiro Nakamura (Osaka, Japan)

11:22–11:32 FC18 2-year (yr) results and biomarker analysis of a phase 2, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma (MEL) Reinhard Dummer (Zurich, Switzerland)

11:35–11:45 FC19 A retrospective chart review study of realworld use of talimogene laherparepvec in unresectable stage IIIB-IVM1a melanoma in four European countries A.C.J. van Akkooi (Amsterdam, The Netherlands)

11:48–11:58 FC20 Final results of phase II trial (MIRACULUM) of the novel PD-1 inhibitor prolgolimab in patients with advanced melanoma Igor Samoylenko (Moscow, Russia)

BETA HALL

ZETA HALL



Frid

ay, A

pril

24

21w w w . e a d o 2 0 2 0 . c o m


14:30–15:30 WORKSHOP 2PHOTODYNAMIC THERAPYCHAIRS: Merete Haedersdal (Copenhagen, Denmark)

Rolf-Markus Szeimies (Recklinghausen, Germany)

14:30–14:42 PDT for AK, including DL-PDTRolf-Markus Szeimies (Recklinghausen, Germany)

14:45–14:57 PDT for BCCNicolle Kelleners-Smeets (Maastricht, The Netherlands)

15:00–15:12 Optimizing PDTMerete Haedersdal (Copenhagen, Denmark)

15:15–15:27 PDT for AK/NMSC in transplant patientsKatrine Togsverd-Bo (Copenhagen, Denmark)


17:00–18:30 FREE COMMUNICATIONS 4NON-MELANOMA SKIN CANCERCHAIRS: Eduardo Nagore (Valencia, Spain)

Bohdan Lytvynenko (Kyiv, Ukraine)

17:00–17:10 FC21 Bowen’s Disease in the Netherlands (1989-2017): Nationwide Incidence Rates and Risk of Cutaneous Squamous Cell Carcinoma Selin Tokez (Utrecht, The Netherlands)

17:13–17:23 FC22 The Real Burden of Cutaneous Squamous Cell Carcinoma in The Netherlands: Nationwide Incidence Rates of First and Multiple Tumors Selin Tokez (Utrecht, The Netherlands)

17:26–17:36 FC23 5 years recurrence rate of cutaneous squamous cell carcinoma of the head and neck Karolina Nemeth (Chesterfield, UK)

17:39–17:49 FC24 Squamous cell carcinoma of the lip. Ninety-nine invasive tumors treated with Mohs micrographic surgery. Local and regional recurrence. Prognostic factors Gonzalez Abel (Buenos Aires, Argentina)

17:52–18:02 FC25 A Multidisciplinary Consensus on the Treatment of Patients with Advanced Cutaneous Squamous Cell Carcinoma Scott M. Dinehart (Miami, USA)

18:05–18:15 FC26 Efficacy and Safety of Pembrolizumab for Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC): Phase 2 KEYNOTE-629 Study Jean-Jacques Grob (Paris, France)

18:18–18:28 FC27 Efficacy and safety of immune checkpoint inhibitor cemiplimab in patients with locally advanced or metastatic squamocellular carcinoma Giulia Spallone (Rome, Italy)

ZETA HALL

ZETA HALL

Friday, April 24



Frid

ay, A

pril

24




Saturday, April 25ALFA HALL BETA HALL ZETA HALL

08:30–10:00 DERMATOSCOPY COURSE 2 SYMPOSIUM 21

10:00–10:30 COFFEE BREAK, VISIT TO THE EXHIBITION

10:30–12:00 SYMPOSIUM 22Occupational skin cancers

12:00–13:00 KEYNOTE LECTURES 4Challenging cases: dermoscopy quizChallenging cases: dermoscopy quiz

13:00–13:30 CLOSING CEREMONY & AWARDS

Satu

rday

, Apr

il 25

23w w w . e a d o 2 0 2 0 . c o m


Saturday, April 2509:00–10:00 DERMATOSCOPY COURSE 2 PART I

CHAIRS: Giuseppe Argenziano (Naples, Italy)Giovanni Pellacani (Modena, Italy)

09:00–09:25 Facial melanoma Giovanni Pellacani (Modena, Italy)

09:30–09:55 The inverse approach for facial lesions Giuseppe Argenziano (Naples, Italy)

10:00–10:30 COFFEE BREAK

10:30–12:00 DERMATOSCOPY COURSE 2 PART IICHAIRS: Giuseppe Argenziano (Naples, Italy)


10:30–10:55 The BRAAFF algorithm for acral lesions Aimilios Lallas (Thessaloniki, Greece)

11:00–11:25 A quiz for the audience All faculty

12:00–13:00 KEYNOTE LECTURES 4CHAIRS: Aimilios Lallas (Thessaloniki, Greece)


12:00–12:25 Challenging cases: dermoscopy quiz Giovanni Pellacani (Modena, Italy)

12:30–12:55 Challenging cases: dermoscopy quiz Aimilios Lallas (Thessaloniki, Greece)

13:00–13:30 CLOSING CEREMONY & AWARDSCHAIRS: Matilda Bylaitė-Bučinskienė (Vilnius, Lithuania)


08:30–10:00 SYMPOSIUM 21RARE SKIN TUMORSCHAIRS: Judith Oláh (Szeged, Hungary)

Peter Arenberger (Prague, Czech Republic)

08:30–08:47 TBDTBD

08:50–09:07 TBDTBD

09:310–09:27 TBDTBD

ALFA HALL

ALFA HALL

ALFA HALL

ALFA HALL

BETA HALL



Satu

rday

, Apr

il 25




Saturday, April 2510:00–10:30 COFFEE BREAK. VISIT TO THE EXHIBITION

10:30–12:00 SYMPOSIUM 22STAKEHOLDER’S SESSION: OCCUPATIONAL SKIN CANCERSCHAIRS: Swen Malte John (Osnabrück, Germany)

Andrea Bauer (Dresden, Germany)

10:30–10:35 WelcomeAndrea Bauer (Dresden, Germany) Swen Malte John (Osnabrück, Germany)

10:35–10:48 UV exposure in outdoor workers across Europe Timo Heepenstrick (Sankt Augustin, Germany)

10:51–11:04 Is basal cell carcinoma in outdoor workers an occupational disease?Andrea Bauer (Dresden, Germany)

11:07–11:20 Is malignant melanoma in outdoor workers an occupational disease? Swen Malte John (Osnabrück, Germany)

11:23–11:36 Efficacy of sunscreens in protecting against UVB radiation Sanja Kezic (Amsterdam, The Netherlands)

11:39–11:52 Current standards in prevention and therapy of actinic keratosis and cutaneous squamous cell carcinomaClaas Ulrich (Berlin, Germany)

11:52–11:55 Questions

11:55–12:00 Wrap up

BETA HALL



Satu

rday

, Apr

il 25

EADO CONGRESS SCIENTIFIC POGRAMME · 10:00–10:18 The beginners guide to avoid mistakes Giuseppe...

Documents

Transcript of EADO CONGRESS SCIENTIFIC POGRAMME · 10:00–10:18 The beginners guide to avoid mistakes Giuseppe...